Education
About Us
Working with TipRanks
Follow Us
Immuneering (IMRX)
NASDAQ:IMRX
IMRX Stock Chart & Stats
$6.49
-$0.24(-10.17%)
At close: 4:00 PM EST
$6.49
-$0.24(-10.17%)
Day’s Range― - ―
52-Week Range$1.10 - $10.08
Previous CloseN/A
Volume3.55M
Average Volume (3M)2.87M
Market Cap
$365.60M
Enterprise Value$98.92M
Total Cash (Recent Filing)$26.36M
Total Debt (Recent Filing)$4.00M
Price to Earnings (P/E)―
Beta2.50
Next Earnings
Nov 06, 2025EPS Estimate
-0.41Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.40
Shares Outstanding60,530,140
10 Day Avg. Volume1,720,371
30 Day Avg. Volume2,865,825
Financial Highlights & Ratios
PEG Ratio-0.13
Price to Book (P/B)1.59
Price to Sales (P/S)0.00
P/FCF Ratio-1.20
Enterprise Value/Market Cap0.27
Enterprise Value/Revenue136.19
Enterprise Value/Gross Profit-1.24K
Enterprise Value/Ebitda-1.55
Forecast
1Y Price Target
$15.60Price Target Upside140.37% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Bulls Say, Bears Say
Bulls Say
Clinical Trial DevelopmentsAnalysts expect a positive move in IMRX following the 9-month update for atebimetinib plus mGnP in PDAC patients.
Financial OutlookThere is significant upside potential in the stock at current levels, ahead of its data for the Ph 2a study of atebimetinib + GnP in 1L PDAC.
Strategic PartnershipsThe announcement of a new clinical supply agreement with Lilly for evaluating a combination therapy in certain NSCLC patients significantly boosted the stock.
Bears Say
Clinical Trial DelaysOther atebimetinib clinical trial combination arms are now expected to initiate in 2026 instead of the previously planned 2025.
Efficacy ComparisonAtebimetinib's efficacy is similar or slightly worse versus Dara, raising the question if physicians will prefer it in 1L to preserve options for 2L.
Safety ConcernsThe safety profile deteriorated slightly with higher percentages of neutropenia, anemia, and fatigue.
Immuneering News
IMRX FAQ
What was Immuneering’s price range in the past 12 months?
Immuneering lowest stock price was $1.10 and its highest was $10.08 in the past 12 months.
What is Immuneering’s market cap?
Immuneering’s market cap is $365.60M.
When is Immuneering’s upcoming earnings report date?
Immuneering’s upcoming earnings report date is Nov 06, 2025 which is in 7 days.
How were Immuneering’s earnings last quarter?
Immuneering released its earnings results on Aug 13, 2025. The company reported -$0.4 earnings per share for the quarter, the consensus estimate of -$0.4 by $0.
Is Immuneering overvalued?
According to Wall Street analysts Immuneering’s price is currently Undervalued.
Does Immuneering pay dividends?
Immuneering does not currently pay dividends.
What is Immuneering’s EPS estimate?
Immuneering’s EPS estimate is -0.41.
How many shares outstanding does Immuneering have?
Immuneering has 60,530,140 shares outstanding.
What happened to Immuneering’s price movement after its last earnings report?
Immuneering reported an EPS of -$0.4 in its last earnings report, expectations of -$0.4. Following the earnings report the stock price went down -5.59%.
Which hedge fund is a major shareholder of Immuneering?
Currently, no hedge funds are holding shares in IMRX
Immuneering Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$15.60 (140.37% Upside)
$15.60 (140.37% Upside)
Insider Transactions
Bought Shares
Worth $152.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 7.3%
Last 30 Days ▲ 55.5%
Last 30 Days ▲ 55.5%
Technicals
SMA
Positive
20 days / 200 days
Momentum
150.44%
12-Months-Change
Fundamentals
Return on Equity
-130.47%
Trailing 12-Months
Asset Growth
-48.04%
Trailing 12-Months
Company Description
Immuneering
Immuneering Corporation (IMRX) is a biopharmaceutical company focused on developing innovative drug candidates for the treatment of cancer and other diseases. The company's approach is centered around its proprietary platform that harnesses computational biology to unravel complex biological data and identify potential therapeutic targets. Immuneering aims to advance precision medicine by creating effective treatments that can precisely target specific disease pathways, offering new hope for patients with unmet medical needs.
IMRX Stock 12 Month Forecast
Average Price Target
$15.60
▲(140.37% Upside)
Technical Analysis
Larimar Therapeutics
―
Rocket Pharmaceuticals
―
I-MAB
―
Invivyd
―
Aura Biosciences Inc
―
Ownership Overview
10.03% Insiders
2.33% Mutual Funds
0.05% Other Institutional Investors
85.87% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---